Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, FSCAI is Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine.
Dr. Mehran is currently Professor of Medicine, Cardiology and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai in New York. She is also Director of Interventional Cardiovascular Research and Clinical Trials at The Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai Hospital where, over the past five years, she has led the development of a globally-respected data and clinical coordination center to support large, multicenter, multinational clinical trials designed, by her team, to help clinicians improve outcomes and quality of life for patients undergoing interventional cardiovascular procedures. In recent years, her work has had a special emphasis on gaining a deeper understanding of anticoagulation and antiplatelet regimens post angioplasty and transcatheter valve replacement; and collection and interpretation of sex-specific data in cardiovascular clinical trials.
Dr. Mehran serves on editorial board of multiple peer reviewed journals, including Journal of the American College of Cardiology, Circulation, and Circulation Research. She currently serves on the board of trustees of SCAI, as a member of the Program Committee for the American Heart Association Scientific Sessions, as a member of the board of directors for Harboring Hearts, and as Program Chair for Society of Cardiac Angiography and Interventions (SCAI- WIN (Women in Innovations)) Initiative, and is also the Chief Scientific Officer of the Clinical Trials Center at the Cardiovascular Research Foundation (NYC).
TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at...
US Cardiology Review 2020;14:e04.
Interventional Cardiology Review 2018;13(2):93–8.
Guest Editorial: A Brave New World for Non-vitamin K Antagonist Oral Anticoagulants: Have We seen...
US Cardiology Review 2017; 11(1):37–8